What is Musely?
Musely is a digital health platform that bridges the gap between top dermatologists and patients, offering accessible, quick, and affordable personalized prescription treatments. Leveraging a science-rooted approach, the company delivers freshly compounded medications for various conditions including skin issues, hair loss, and menopause directly to patients' homes. Founded by experienced Silicon Valley entrepreneurs, Musely aims to democratize access to effective healthcare solutions through its technology-driven, patient-centric model.
How much funding has Musely raised?
Musely has raised a total of $372.2M across 2 funding rounds:
Series A
$6.2M
Series B
$16M
Series A (2014): $6.2M with participation from InnoSpring, GSR Ventures, and DCM Ventures
Series B (2014): $16M, investors not publicly disclosed
Key Investors in Musely
InnoSpring
InnoSpring is a venture capital firm that likely focuses on early-stage technology and research & development companies, providing seed funding to promising startups.
GSR Ventures
GSR Ventures is a venture capital firm known for investing in technology companies, particularly in areas like semiconductors, enterprise software, and internet services, often with a focus on China.
DCM Ventures
DCM Ventures is a prominent venture capital firm that invests in early-stage technology companies, with a strong track record in sectors such as internet, mobile, and software.
What's next for Musely?
With the recent injection of major strategic capital, Musely is poised for accelerated expansion. This enterprise-level funding is expected to fuel further development of its platform, enhance its service offerings, and broaden its market reach. The company's focus on personalized, science-backed treatments delivered conveniently suggests a strategic push towards solidifying its position as a leader in the telehealth and personalized medicine space, potentially exploring new therapeutic areas and deepening its dermatologist network.
See full Musely company page
